TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02876705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
Study: NCT00646178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg adalimumab eow Week 0 - Week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: placebo eow Week 0 - Week 12
Study: NCT04536467

Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin
Description: chemotherapy+goserelin

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: standard chemotherapy
Study: NCT05187663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic (PDT) group
Description: Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH \& Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine (CHX) group
Description: Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
Study: NCT01618903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
Study: NCT04416295

Intervention type: DEVICE
Group type: OTHER
Intervention: LifePod
Description: LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifePod
Description: LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
Study: NCT02253758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be injected as a continuous infusion by TCI intravenously
Study: NCT01677169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Noni juice
Description: Ingestion of noni juice, a source of iridoids, daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Noni juice
Description: Ingestion of noni juice, a source of iridoids, daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04976088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 140 mg medicated plaster
Description: Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector
Description: Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Placebo plaster, topical application once a day.
Study: NCT01929148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic bilateral salpingectomy
Description: Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic myomectomy without PBS
Description: Standard laparoscopic myomectomy without salpingectomy
Study: NCT04324307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1/CTLA4 BsAb
Description: PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1/CTLA4 BsAb
Description: PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1/CTLA4 BsAb
Description: PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GP
Description: Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
Study: NCT03665480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-SCF
Description: In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
Study: NCT03408236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Active Comparator
Study: NCT02394353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transient hepatic elastography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transient hepatic elastography
Study: NCT04871178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: Eight, 2-hour instructor-led MBI group sessions once a week for 8 weeks, combined with formal meditative training at home for 20 minutes per day, 6 days a week.~Course material consists of facts booklet, weekly training manuals, audio recordings on a CD, with the five formal guided meditative exercises (body scan, breathing anchor, breathing space, mindful movements, sitting meditation).~The weekly home-work also included informal training of being present in daily life activities.~The program is provided according to the standard MBI protocol. Compared to MBSR and MBCT durations of formal meditative practices are shorter and no 'all-day in silence' session is included. Because of participants' physical limitations and safety, the 'mindful movements' sequence, is adapted and performed in a sitting position.~Adherence to the MBI was followed by self-reported weekly training in manuals asked to be submitted at group sessions.
Study: NCT06532110

Intervention type: OTHER
Intervention: Endoscopy/Colonoscopy
Description: Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
Study: NCT04497441

Intervention type: OTHER
Intervention: Electronic Survey questionnaire
Description: This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms.
Study: NCT02800707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucralose
Description: Sweetner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stevia
Description: Sweetner
Study: NCT03669003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gelfoam slurry
Description: Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided percutaneous lung biopsy
Description: Biopsy of a lung nodule under CT guidance.
Study: NCT00949247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
Study: NCT02671487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
Study: NCT02566395

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI containing 1 x 10E8/kg donor T-cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Stem Cell Transplantation
Description: 2-10 x 10E6/kg donor CD34+ selected cells
Study: NCT02246998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STB
Description: 150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVD
Description: 200/300 mg FDC tablet administered orally once daily with food
Study: NCT02074878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crixotinib 200 mg and Sunitinib Cohort 1
Description: Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
Study: NCT02200055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodystat Quadscan 4000
Description: Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment
Study: NCT00571142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + Pars plana vitrectomy
Description: 2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + pars plana vitrectomy
Description: 2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
Study: NCT03575611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT02246998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR
Description: 600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg capsule administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg capsule administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: 600/300 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
Study: NCT01686711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-4833 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-4833 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04088097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating
Description: Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Educational and informational materials on adolescent health and nutrition.
Study: NCT01473654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT tool
Description: Use of ADAPT shared goal setting tool in EMR
Study: NCT01075074

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
Study: NCT02074878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crixotinib 250 mg and Sunitinib Cohort 2
Description: Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib & Sunitinib 37.5 mg Cohort 3
Description: Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
Study: NCT01154166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ReQuip PR
Description: If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00297817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serogroup B meningococcal vaccine
Description: 0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serogroup B meningococcal vaccine
Description: 0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: serogroup B meningococcal vaccine
Description: 0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
Study: NCT04407897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
Study: NCT04134897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles
Study: NCT03781934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Description: MIV-818 - oral capsules; pembrolizumab - IV
Study: NCT04134897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles
Study: NCT03781934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Description: MIV-818 - oral capsules; lenvatinib - oral capsules
Study: NCT03761706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in Physical Activity
Description: Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
Study: NCT03575611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT